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Abstract
Background: Glutaminyl cyclase (QC) forms the pyroglutamyl residue at the amino terminus of
numerous secretory peptides and proteins. We previously proposed the mammalian QC has some
features in common with zinc aminopeptidases. We now have generated a structural model for
human QC based on the aminopeptidase fold (pdb code 1AMP) and mutated the apparent active
site residues to assess their role in QC catalysis.
Results: The structural model proposed here for human QC, deposited in the protein databank
as 1MOI, is supported by a variety of fold prediction programs, by the circular dichroism spectrum,
and by the presence of the disulfide. Mutagenesis of the six active site residues present in both
1AMP and QC reveal essential roles for the two histidines (140 and 330, QC numbering) and the
two glutamates (201 and 202), while the two aspartates (159 and 248) appear to play no catalytic
role. ICP-MS analysis shows less than stoichiometric zinc (0.3:1) in the purified enzyme.
Conclusions:  We conclude that human pituitary glutaminyl cyclase and bacterial zinc
aminopeptidase share a common fold and active site residues. In contrast to the aminopeptidase,
however, QC does not appear to require zinc for enzymatic activity.
Background
The synthesis of biologically active peptide hormones and
neurotransmitters begins with precursor proteins under-
going maturation via different processing enzymes. Pro-
hormone convertase catalyzes cleavage within precursor
proteins at paired basic amino acid residues [1] while car-
boxypeptidase removes these basic residues [2]. Several
peptide hormones and neurotransmitters, such as thyro-
tropin-releasing hormone, are further modified at their
termini. These termini modifications appear to be neces-
sary for recognition of a receptor-binding site or protec-
tion of the peptide from exopeptidases. A frequent
terminus modification is the oxidative cleavage by pepti-
dyl α-amidating monooxygenase [3] of a carboxyl termi-
nal glycine to form a terminal amide. The amino terminus
can be acylated or, in the case of an N-terminal glutaminyl
residue, can be cyclized to the pyroglutamyl residue with
the accompanying release of the amide nitrogen as
ammonia. This last reaction is catalyzed by glutaminyl
cyclase (EC 2.3.2.5).
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In 1965 Messer and Ottesen identified and purified the
first known form of glutaminyl cyclase (QC) from papaya
latex [4]. The laboratories of J.S. Kizer and J. Spiess concur-
rently published the initial identification of QC in porcine
and bovine pituitaries, respectively [5,6] and, as expected,
QC was found to be localized within secretory vesicles [7].
Subsequent cloning of the bovine and human QC cDNA
revealed very similar proteins of 361 amino acids, includ-
ing a nearly thirty amino acid endoplasmic reticulum sig-
nal sequence [8,9]. QC homologs can be discerned in the
genomes of a wide variety of organisms including yeast
[10], with the human QC gene residing on chromosome
2 (NCBI LocusID: 25797).
Human pituitary QC has been expressed in bacteria,
although this has often resulted in protein with little activ-
ity, stability, or solubility, or active protein with a non-
cleavable GST fusion [9-12]. Thus, functional and struc-
tural characterization of QC has been limited. Site
directed mutagenesis of the two conserved cysteines
revealed neither was essential to enzyme function [12].
Recent mutational analysis of four highly conserved histi-
dine residues indicated that two residues participated in
catalysis and two in substrate binding [10]. Taken
together with the apparent lack of nucleophilic essential
amino acids [5,12], this suggests catalysis by mammalian
QC proceeds via general acid/base promotion of the direct
cyclization of the terminal glutamine as we have proposed
for the papaya enzyme [13,14].
Glutaminyl cyclase has also been purified from papaya
latex, but animal and plant forms of QC have no discern-
able primary sequence identity [15]. We hypothesized
previously [10] that, while animal and plant forms of QC
may be utilize similar catalytic mechanisms, they have dif-
ferent tertiary structures and probably represent two inde-
pendent families of enzymes. Taken together with
previous work on papaya QC, this study demonstrates
that the mammalian and plant QC forms are indeed struc-
turally unrelated, while providing evidence of a structural
relationship between mammalian QC and the bacterial
zinc aminopeptidase family.
Results
Features of the model of human QC
We predict that human QC and the bacterial zinc
exopeptidases share a similar fold (Figure 1). This consists
of a central 8-stranded β-sheet, which is of a mixed paral-
lel/anti-parallel nature. The sheet is flanked by six α-heli-
ces on one side and three on the other. The proposed
active site lies at the C-terminal end of the central two β-
strands, and is mostly comprised of residues from loop
regions.
The sequence identity between human QC and members
of the aminopeptidase family is low: between QC and
Vibrio proteolyticus aminopeptidase (pdb code 1AMP,
[16]), for example, it is 16% over the entire length of the
alignment. Nevertheless the fold recognition program
"Fugue" assigns QC to the "bacterial exopeptidases" fam-
ily with a Z-score of 26.5. Z-scores with values above 6 cor-
respond to "certain" assignments (>99% probability).
Fugue is amongst the most sensitive fold recognition pro-
grams currently available [17]. It considers not just the
amino acid type, but also its environment, up-weighting
those amino-acid residues likely to be conserved through
evolution. Conservation of these important features leads
Fugue to give the confident assignment in this case.
The sequence alignment (Figure 2) and model have sev-
eral convincing features. The Psipred prediction of sec-
ondary structure corresponds extremely well to that of the
aminopeptidase family (Figure 2). This family consists of
aminopeptidases from Vibrio proteolyticus (pdb code
1AMP) and Streptomyces griseus (pdb code 1XJO, [18], and
the catalytic domain of carboxypeptidase G2 from Pseu-
domonas (pdb code 1CG2, [19]). Fugue does not use pre-
dicted secondary structure to determine either the most
likely family assignment for a given sequence nor the
alignment, and so the correlation gives increased confi-
dence in the fold assignment and alignment. The N-linked
glycosylation sites (Asn 49 and Asn 296) are solvent
exposed in the model. The cysteine residues are posi-
tioned such that they are able to form a disulfide bond.
This bond is in a different position in the QC model as
compared to that in template structures 1AMP and 1XJO
(the disulfide is absent in 1CG2). In the QC model the
disulfide is between α-helix 4 and the third β-strand of the
sheet, and as such is completely buried in the core and
unlikely to play any direct role in catalysis. The reported
effect on activity produced by reducing the disulfide [11]
is therefore likely to be structural.
We predict from the model, therefore, that human QC has
a mixed α-helix/ β-strand structure that, consistent with
the previous prediction, Asn 49 is the likely glycosylation
site, and that the two cysteine residues (139 and 164)
should be in the disulfide-bonded rather than free thiol
form. It should be noted that these features were not used
as constraints when aligning the sequences. Their experi-
mental validation can, therefore, serve as a confirmation
of the model.
Interestingly, the active site residues (His 140, Asp 159,
Glu 201, Glu 202, Asp 248 and His 330, QC numbering)
in 1AMP are conserved in the QC model (Figure 3), and
probably adopt a similar conformation. Five of these resi-
dues form a metal binding site for two zinc ions in 1AMP,BMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/2
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and it would appear that a metal binding site could also
be present in human QC. However, there is conflicting
evidence for the presence of zinc in human QC (see
discussion).
Analysis of papaya QC
In contrast to human QC, the papaya enzyme produces
hits with lower confidence levels. It is predicted by Fugue
[17] as having similarity to the cytochrome cd1-nitrite
reductase family, specifically to the β-sheet domain,
which is an eight-bladed β-propeller structure (pdb codes
1AOQ and 1NIR, Z-score = 8.1) and to bacterial amine
dehydrogenase (pdb code 1JJU, chain B, Z-score = 7.4),
which is a seven-bladed β-propeller. Again in contrast to
human QC, papaya QC is predicted by Psipred to have an
entirely β-sheet structure, which is consistent with the CD
spectrum [20]. Given the relatively low score, the ambigu-
ity regarding the number of blades of the propeller and
the difficulty of building accurate models of proteins with
repetitive secondary structure [21], we have not built a
model of papaya QC. However, it is clear that the papaya
QC is structurally distinct from the human QC having an
all-beta structure, possibly a β-propeller.
Secondary structure and metal analyses
Secondary structural characteristics of DES hQC and the
mutant forms (data not shown) were examined by circu-
lar dichroism (Figure 4). Samples were prepared as
described in the methods section and then analyzed at
Tulane University with an OLIS CD spectrophotometer.
Eight scans from 260 nm to 196 nm were obtained on a 6
µM sample. The resulting spectrum indicated that DES
hQC contains 32% α-helix, and 17% β-sheet, a secondary
structure composition that correlates well with the Vibrio
proteolyticus aminopeptidase, which contains 35% α-
helix, and 17% β-sheet.
Metal content was determined by ICP-MS as described in
Methods. An average of 2.0 nmol/ml Zn were obtained for
every 6.2 nmol/ml QC, giving a molar stoichiometry of
0.32:1 Zn:QC.
Active site identification
Four QC acidic amino acid residues were selected for site-
directed mutagenesis to alanine based on their conserva-
tion between species [10] as well as their presence in the
bacterial aminopeptidase active site (see figure 3 and
model analysis above). Mutations in either glutamate 201
Ribbon diagram of hQC theoretical model Figure 1
Ribbon diagram of hQC theoretical model. Ribbon diagram of secondary and tertiary structures of Vibrio aminopeptidase 
(PDB 1AMP) and human glutaminyl cyclase (PDB 1MOI). Structures are oriented so that active sites are on the right of the 
molecule. Illustration was generated with DeepView 3.7 using solid open GL rendering and colored by secondary structure 
succession.BMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/2
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Sequence alignment of hQC and structural templates Figure 2
Sequence alignment of hQC and structural templates. Alignment of amino acid sequence of Vibrio aminopeptidase 
(PDB code 1AMP), Streptomyces aminopeptidase (PDB code 1XJO) Pseudomonas carboxypeptidase G2 (PDB code 1CG2) and 
human pituitiary glutaminyl cyclase (bottom line). Numbers along the top indicate the alignment position. Numbers in paren-
theses on the left hand side indicate the sequence numbering for the first amino acid in on that line for each sequence. Bars 
indicate secondary structure (dark bars for helices, light bars for strands) for those sequences with experimentally determined 
structures. Bars underneath the alignment (labeled "Psipred") indicate predicted secondary structure for the human QC 
sequence.
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1amp ( 1 ) MPPITQQATVT
1xjo ( 1 )
1cg2a ( 26 ) QKRDNVL F
QC M AGGRHRRVVGTLHLLLLVAALP W ASRGVSPSASA WPEEKNYHQPAILNS
60 70 80 90 100
1amp ( 12 ) A W LP Q V D A S QIT G TISS LESF-----T N RF YTT-TS G A Q A S D W IA S E W Q A
1xjo ( 1 ) APDI PLANVKAHLTQLST IAANNGGNRAHGR -PGYKASVDYVKAKLDA
1cg2a ( 34 ) QAATD-EQPAV IKTLEKLVNI - - - - - -ETGTGDAEGIAAAGNFLEAELKN
QC SALRQIAEGTS I SEM WQNDLQ- - -PLL I ERYPGSPGSYAARQHIMQR IQR
110 120 130 140 150
1amp ( 56 ) LSAS-LPNASVKQVSHS- -GYNQKSVVMTITGSEAPDEWIVIGGHLDSTI
1xjo ( 48 ) A------G YTTTLQQFTSGGATGYNLIAN WPG-GDPNKVLM AGAHLDSVS
1cg2a ( 77 ) L------G F T V T RS KS A-G L V V G D NIV G KIK G R G--G K N LLL M S H M D T V Y
QC LQ AD W VLEIDTFLSQTPYGYRSFSNI ISTLNP--TAKRHLVLACHYDSKY
160 170 180 190 200
1amp ( 103 ) G S H T N E---------Q S V A P G A D D D A S GIA A V TE VIR V LS E N--------
1xjo ( 91 ) -----------------S G A GIN D N G S G S A A V LET A L A VS R A--------
1cg2a ( 118 ) L K GIL A K A P F R V E G D K A Y G P GIA D D K G G N A VIL H TL KLL KE Y--------
QC FS H W N N R---------- VF V G A T D S A VP C A M M LEL A R A L D K KLLS L KT VS
210 220 230 240 250
1amp ( 136 ) N F Q P K RSIA F M A Y A A EE V-----------G LR G S Q D L A N Q Y KS E------
1xjo ( 116 ) G Y Q P D K H LRF A W W G A EEL-----------G LIG S KF Y V N N LP S A------
1cg2a ( 160 ) G V R D Y G TIT V LF N T D EE K-----------G SF G S R D LIQ EE A K-------
QC DSKPDLSLQLIFFDGEEAFLH WSPQDSLYGSRHLAAKMASTPHPPGARGT
260 270 280 290 300
1amp ( 169 ) -G K-N V VS A L Q L D M T N Y K G S A Q D V VFIT D YT D------S N F T Q YLT Q L M D
1xjo ( 149 ) -D RS KL A G YL N F DIG SP N P G---YF V Y D D D--------P VIE KTF K N YF A
1cg2a ( 192 ) ----L A D Y V LSF EP TS A G----D E KLS L G T-F N A G E G G K KL V D K A V A Y Y K
QC SQLHG M DLLVLLDLIGAPNPTFPNFFPNSAR WFERLQ AIEHELHELGLLK
310 320 330 340 350
1amp ( 211 ) E YLP S LT Y G F D T C G Y A--C S D H A S W H N A G YP A A M P F--ES KF N D------
1xjo ( 188 ) G L--N VP TEI--------R S D H A P F K N V G VP V G G LF--T G A G y T KS A A Q A
1cg2a ( 346 ) EA - -GGTLGVEERTGG- -GTDAAYAAL SGKPV I ESLGL PGFGYHSD- - - -
QC D H S LE G R YF Q N YS Y G G VIQ D D HIP F L R R G VP VL H LIP SP-----------
360 370 380 390 400
1amp ( 251 ) ----------Y N P RIH TT Q D TL A N S D P T G S H A K KF T Q L G L A Y AIE M G S A T
1xjo ( 232 ) QKWGGTAGQAFDRCYHSSCDSLSNIN- -DTALDRNSDAAAHAIWTLSS
1cg2a ( 388 ) ----------------------K A E Y V DIS AIP R R L Y M A A R LI M D L G A G
QC ----------FP E V W H T M D D N--EE N L D ES TID N L N KIL Q VF VLE YL H L ( 325 )
( 236 )
( 286 )
( 186 )
( 146 )
(9 8 )
(5 1 )
(1 )
Psipred
Psipred
Psipred
Psipred
Psipred
Psipred
Psipred
PsipredBMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/2
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or 202 resulted in completely inactive QC forms. These
mutants interact as well as unmutated enzyme with the
affinity column, suggesting that the binding site was not
disrupted; furthermore, fluorescence scans and CD spec-
troscopy revealed no apparent changes in structure.
Kinetic studies on aspartate 159 and 248 mutants revealed
no significant differences in the Km from unmutated DES
hQC (1.4 ± 0.2 (unmutated), 1.5 ± 0.3 (D159), and 1.4 ±
0.4 (D248) mM, respectively) and only a slight decrease
in the Vmax of D159 (3.7 ± 0.4 (unmutated), 1.5 ± 0.2
(D159), and 3.3 ± 0.5 (D248) µmol/min/mg,
respectively).
Discussion
As a peptide-processing enzyme in the mammalian secre-
tory pathway, QC is susceptible to a variety of posttransla-
tional modifications. Recently we showed that at least one
of the two predicted N-linked glycosylation sites is indeed
glycosylated in the insect-expressed protein and one, if
not both, sites in the native tissue QC contain glycans as
well [22]. Mutagenesis of both sites showed that the pres-
ence or absence of glycans had no apparent effect on QC
enzymatic activity. The glycans, then, either have a cellular
role such as localization or they are simply fortuitous.
Also, consistent with the oxidizing environment of the
secretory pathway is the finding that the two cysteine
residues in QC are disulfide-bonded [22]. The presence of
a disulfide bond was also recently reported by Schilling
[11] in human QC expressed in yeast. They postulated a
role for this disulfide bond in enzyme activity since addi-
tion of high concentrations of reducing agents result in
loss of activity. Our previous mutagenesis of these two
cysteine residues [12] indicate that they are not directly
involved in catalysis, making it likely that they play a role
in stabilizing an active form of enzyme tertiary structure.
Indeed, the model predicts the disulfide bond is immedi-
ately behind the enzyme active site and crosslinks two
pieces of secondary structure directly connected to loops
containing active site residues.
Tertiary structure examination of QC began with the
development of a predicted model (pdb code 1MOI)
based on a bacterial zinc aminopeptidase fold as
described in the methods section and predicted previously
[10]. DES hQC secondary structure composition deter-
mined using circular dichroism shows DES hQC to con-
tain 32% α-helix, 17% β-sheet, and 52% random coil, a
secondary structure composition that corresponds well
both to the CD analysis of the bacterial aminopeptidase
which is 35% α-helix, 17% β-sheet, and 48% coil [23] and
the secondary structure composition of the model (33%
α-helix, 24% β-sheet, and 43% coil). Not only does the
proportion of each secondary structure type correspond
well between the QC model and the bacterial aminopepti-
dase family, but also the predicted linear arrangement and
position of each secondary structural element from
Psipred corresponds well with the aminopeptidases (Fig-
ure 2). In addition, the model predicts that the conserved
cysteine residues are in position to form a disulfide bond,
Predicted active site of human glutaminyl cyclase Figure 3
Predicted active site of human glutaminyl cyclase. 
Figure 5 represents the five conserved human QC residues 
corresponding to the zinc ligands of the bacterial aminopepti-
dase plus the conserved glutamate corresponding to the gen-
eral base of the aminopeptidase. QC numbering from the top 
(clockwise): His 330, Glu 202, Glu 201, His 140, Asp 248, 
Asp 159. See Table 1 for comparisons with 1AMP.
Circular dichroism spectrum of DES hQC Figure 4
Circular dichroism spectrum of DES hQC. Circular 
dichroism of 6 µM DES hQC in 5 mM sodium phosphate 
buffer, pH 6.0 from 196 to 260 nm.
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a prediction experimentally confirmed in our previous
study [22]. Further, both N-linked glycosylation sites are
located on the exterior of the protein model.
In contrast with human QC, papaya QC is an all β-sheet
protein. This has been shown by Oberg [20], based on CD
spectra. The computational methods used here are in
agreement with this result, in that β-structure is predicted
by Psipred and the weak similarity to a β-propeller struc-
ture is also suggestive of a β-structure. In addition, the lack
of sequence similarity between the two enzymes [15], and
the dramatic differences in susceptibility to inhibition by
both competitive inhibitors and diethylpyrocarbonate
[10,24] suggest that the two enzymes are unlikely to be
divergently evolved.
Convergently evolved functions and/or mechanisms are
not without precedent. The most widely known example
is the catalytic triad, which was first found in protease chy-
motrypsin [25], and subsequently in the structurally unre-
lated but functionally similar subtilisin [26]. It has since
been observed in lipases [27] and recently in
acetylhydrolase [28]. All of these enzymes share related
functions and similar mechanisms, but have quite differ-
ent folds.
Holbrook and Ingram [29] have suggested a set of tests for
distinguishing divergent and convergent evolution in
enzymes. In descending order of importance they are:
sequence similarity at the DNA level, sequence similarity
at the amino-acid level, similarity of three-dimensional
structure, similarity of enzyme-substrate interactions, sim-
ilar catalytic mechanism and segments of the chain essen-
tial for catalysis are in the same sequence. The catalytic
triad containing enzymes fail every test except for similar
mechanism and so are generally accepted as examples of
convergent evolution. Similar function with different fold
and lack of sequence similarity is currently used as evi-
dence for convergence (for example [30]). Russell [31] has
looked for similar spatial arrangements of catalytic resi-
dues in proteins that share no fold similarity, and there-
fore are unlikely to be divergently evolved. In a search of
the protein structure database he identified 22 pairs of
proteins that have similar function but different folds, and
are therefore likely to be convergently evolved. Similarly,
we find that human and papaya QCs are unrelated at the
DNA and amino-acid levels, are likely to have different
structures, and yet have similar functions. In the absence
of more structural studies we are unable to tell whether
the least important of Holbrook and Ingram's criteria are
met, but given the known structural differences this seems
highly unlikely.
Six amino acid residues are predicted to be at the active
site of QC based on their location in the zinc aminopepti-
dase fold (Figure 3, Table 1). These are picked up quickly
in a PSI-BLAST [32] search with the human QC protein
sequence. Two of these, QC histidines 140 and 330, were
previously shown to be essential catalytic residues [10].
The other four residues, glutamates 201 and 202 and
aspartates 159 and 248, were examined in this study.
Mutagenesis of the two glutamates showed both to be
essential for QC enzymatic activity. The aminopeptidase
counterpart of QC Glu 201 acts as a general base to pro-
mote water attack on the peptide bond in aminopeptidase
catalysis. A glutamate residue plays the same role in other
well-studied zinc peptide hydrolases such as carbox-
ypeptidase A and thermolysin. It is tempting to speculate
that QC Glu 201 may perform a similar function in the
transamidation reaction of glutaminyl cyclization by pro-
moting attack of the alpha amine on the gamma
carboxamide.
Does human QC contain active site zinc? Our ICP-MS
analysis indicated a stoichiometry of 0.3 mol Zn/mol QC,
effectively ruling out the presence of two zinc atoms and
suggesting the residual zinc presence is adventitious,
although admittedly it is possible some zinc was lost dur-
ing enzyme purification. QC is refractory to metal
chelators such as EDTA, nitrolotriacetic acid [5,10], pep-
tide thiols and boronic acids [24], Glu-Trp, and gamma-
glutamate hydroxamate (unpublished results). In addi-
tion, the enzyme refolds into an active form after denatur-
ation with urea [6,9]. Finally, an absence of metal is
consistent with the observation that mutation of the two
aspartates, which are zinc ligands in the aminopeptidase,
had no effect on QC enzymatic activity. Taken together,
the above evidence argues strongly against a requirement
for zinc at the QC active site.
Schilling et al [24] have recently proposed that QC is a
metalloenzyme based on time dependent inhibition by o-
phenanthroline and dipicolinic acid, as well as the activa-
tion of the inactive QC "apoenzyme" by added zinc. In
contrast, we have observed competitive inhibition (Ki 20
µM) with o-phenanthroline. As Schilling et al. point out,
both o-phenanthroline and dipicolinic acid are planar
heterocyclic compounds. Both can therefore potentially
act as reversible inhibitors just as the imidizole derivatives
they report [5]. It is also curious that cobalt did not reacti-
vate QC in the Schilling study, since it commonly
reactivates zinc peptidases. It remains to be seen, there-
fore, whether the reported reactivation by zinc is due to
replacement of an active site metal, binding of zinc to an
alternative site such as the polyhistidine expression tag, or
an experimental artifact.
The bacterial zinc aminopeptidase fold is found in pro-
teins such as carboxypeptidase G2 [19] as well as the
human tranferrin receptor [3], which exhibits no knownBMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/2
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enzymatic activity. A VAST search of the protein databank
using the Vibrio proteolyticus aminopeptidase (1AMP)
structure reveals a number of similar tertiary structures
including, intriguingly, a pyroglutamate aminopeptidase
(1A2Z) from Thermococcus litoralis. The VAST superimpo-
sition of 1A2Z with 1AMP shows good structural align-
ment with the central beta sheet and connecting helices,
with an alpha carbon RMSD of 3.3 angstroms. Pyrogluta-
mate aminopeptidase is a cysteine peptidase, with the
catalytic triad only slightly offset from the zinc ami-
nopeptidase active site residues described in this paper. It
is clear, then, that the bacterial zinc aminopeptidase fold
is available for a variety of functions other than zinc-cata-
lyzed peptide bond hydrolysis. In the case of QC, it
appears that four of the six critical active site residues of
the aminopeptidase are also essential for QC catalysis,
possibly representing the distant recruitment of catalytic
residues during evolution among hydrolases/amidotran-
ferases that operate on peptide termini.
Conclusions
A theoretical model of human pituitary glutaminyl cyclase
has been generated based on the tertiary structure of the
bacterial zinc aminopeptidase family. Six key active site
residues in the aminopeptidase structure are present in the
QC model, with four of these six residues essential for QC
enzymatic activity. Despite the structural similarity with
the zinc aminopeptidase family, our site directed muta-
genesis, inhibitor studies, and metal analysis argue
strongly against QC being a metalloenzyme.
The structural model proposed here will provide the basis
for interpreting further mutagenic and spectroscopic stud-
ies of this mammalian peptide processing enzyme, as well
as facilitate structural comparisons with the plant glutam-
inyl cyclase family.
Methods
Materials
Peptide substrates were obtained from Bachem. All restric-
tion enzymes and their corresponding buffers were
obtained from Promega. Oligonucleotide primers were
made by Integrated DNA technologies, Inc. Automated
sequencing was performed at UF DNA Core Lab. Muta-
genesis reagents were obtained from Amersham Pharma-
cia Biotech. Human pituitary glutaminyl cyclase cDNA
was expressed in Drosophila cell culture and purified from
serum-free media by affinity chromatography as described
previously [22].
Comparative modeling
Secondary structure predictions were calculated using
Psipred [33]. Homologous proteins of known structure
were identified, and initial sequence alignments were pro-
duced using the Fugue program [17]. Clear homologues
were found: aminopeptidase from Vibrio proteolyticus (pdb
code 1AMP) and Streptomyces griseus (pdb code 1XJO),
and carboxypeptidase G2 from Pseudomonas sp. (pdb code
1CG2). These all belong to the "bacterial aminopepti-
dase" family in the structural alignment database Hom-
strad [34]. The initial alignment was adjusted manually
(Figure 2) and verified using Harmony3 (J. Shi, unpub-
lished), which matches observed substitution frequency
in the alignment with predicted substitution frequency
from standard and environment specific substitution
tables. Models were built with Modeller 6.1 [35,36]. Since
Cys 139 and Cys 164 were within bonding distance in the
initial models, in subsequent models they were built in
the disulfide bonded rather then free thiol form. Five
loops (residues 177–186, 203–215, 227–237, 273–269,
298–304) contained insertions in the QC model relative
to the template structures. These loops were rebuilt with
Rapper [37,38]. As these loops had no equivalent in the
parent structures, they should be considered the least reli-
able parts of the model. Similarly, no homologous resi-
dues were available for the N-terminal 35 residues and
these were therefore omitted. The final model had only a
Table 1: Active site residue comparison. Comparison of positionally identical active site residues in Vibrio proteolyticus aminopeptidase 
and human pituitary glutaminyl cyclase. A designation of "none" means the residue plays no discernable role in the enzymatic reaction.
Aminopeptidase Residue Function in Aminopeptidase QC residue Function in QC
Asp 117 Zn bridge Asp 159 None
His 256 Coordinates Zn #1 His 330 Catalytic
Glu 152 Coordinates Zn #1 Glu 202 Catalytic
His 97 Coordinates Zn #2 His 140 Catalytic
Asp 179 Coordinates Zn #2 Asp 248 None
Glu 151 Catalytic Glu 201 Catalytic
His 230 None His 307 Substrate binding
Met 242 None His 319 Substrate bindingBMC Biology 2004, 2 http://www.biomedcentral.com/1741-7007/2/2
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single Ramachandran outlier (Phe 146), according to the
Rampage program [39]. It has been submitted to the Pro-
tein Data Bank and assigned pdb code 1MOI.
Site-directed mutagenesis
A mutation was introduced into the DES hQC expression
vector using Unique Site Elimination Mutagenesis kit
(Amersham Pharmacia Biotech). This method uses two
primers to incorporate mutations into the same strand of
DNA by in vitro DNA synthesis with T4 DNA polymerase
[40]. Primers were designed to replace the glutamic acids
at postions 201 or 202, and aspartic acids at positions 159
and 248 with alanine while introducing a silent mutation
in the expression vector that deletes a restriction site.
Mutant constructs were confirmed by automated sequenc-
ing at UF DNA Core Lab (Gainsville, FL).
Activity assay
A spectrophotometric assay was used to detect QC activity
as reported by Bateman [41] with the modification that 5
mM Gln-NH2 was routinely used as substrate and 10 µM
bestatin was included. For kinetic analysis, substrate con-
centrations from 0.3 mM to 4 mM were used.
Protein samples (1–5 µg) were run in 10 % NuPAGE as
described in the manufacturers instructions except the
reducing agent, 50 µM DTT, was omitted in non-reduced
samples.
Metal analysis
Purified protein samples were analyzed for metal content
with ICP-MS by the University of Georgia Chemical Anal-
ysis Laboratory. Two independent purifications were
used, with the buffers treated with Chelex 100 to remove
residual zinc. Blanks included buffer alone as well as elu-
tion buffer from a complete purification protocol using
media from nontransfected S2 cells which had been
treated in a manner identical to the QC-expressing S2
cells. Protein was quantified using the predicted molar
extinction coefficient (55 310 M-1cm-1 at 280 nm) and by
SDS-PAGE followed by staining with Coomassie blue,
then densitometry with BSA standards. Both methods
agreed closely.
Secondary structure analysis
Purified protein samples were dialyzed against 5 mM
potassium phosphate buffer, pH 6.0 and then concen-
trated to 6 µM using Microcon Centricon-10 (Amicon).
Data was collected using an OLIS circular dichroism (CD)
spectrophotometer. Fifty data points were collected for
each scan from 196–260 nm with a total of eight scans per
sample. Baseline corrected data were smoothed with a
Gavitsky-Golay filter. The Y-scale was measured in ellipi-
ticity, θ, and set from -40 to 60. Molar ellipiticity, [θ], was
calculated for each data point using the following for-
mula: [θ] = (100 * θ) / (C * n * l) where C = concentration
in mM, n = number of residues, and l = path length of cell
in cm. The molar ellipiticity values were imported into the
K2d program [42] which uses a database comparison to
predict the % α-helix, % β-sheet, and % random coil.
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QC, Glutaminyl Cyclase
ICP-MS, Inductively Coupled Plasma Mass Spectrometry
DES, Drosophila Expression System
PDB, Protein Data Bank
DTT, Dithiothreitol
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electrophoresis
BSA, bovine serum albumin
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